Yidu Tech (2158) H2 2026 earnings summary

Executive summary

• FY2026 marked a turnaround to first full-year profitability, with revenue up 14.6% YoY to RMB819.3m and net profit of RMB78.8m.

• Gross margin expanded to 36.4%; operating cash outflow narrowed 91.2%, and H2 operating cash flow was positive at RMB29.3m.

• YiduCore had processed nearly 9bn authorized medical records covering 1.32bn patient visits, supporting deployment across hospitals, life sciences and health management.

Financial highlights

• Revenue rose 14.6% YoY to RMB819.3m; gross profit increased 24.8% to RMB298.5m and gross margin improved 2.9pp to 36.4%.

• Operating profit was RMB87.8m versus a RMB134.1m loss in FY2025; net profit was RMB78.8m versus a RMB135.2m loss.

• Basic and diluted EPS were RMB0.07, versus losses per share of RMB0.11 in FY2025.

• Operating cash used was RMB22.0m versus RMB248.8m in FY2025; the H2 FY2026 operating cash flow was positive at RMB29.3m.

• Total cash, term deposits, pledged and restricted balances fell to RMB2,079.8m from RMB3,309.1m at 31 March 2025.

Outlook and guidance

• Strategy centers on YiduCore, embedding disease knowledge, medical models and agents into clinical, research, hospital-management and health-service workflows.

• Disease-focused, full-lifecycle solutions in oncology, diabetes, hematological, cardiovascular and cerebrovascular conditions are intended to add revenue and shift project work toward reusable, platform-based offerings.

• Life Sciences plans to expand AI across research design, patient screening, data capture, evidence generation and post-launch value assessment, with emphasis on high-value clients and therapeutic areas.

• Care plans to replicate validated chronic-disease and digital-therapeutics services across more regions and populations; international markets are being explored for repeatable deployments.

• Capital deployment priorities include R&D, global expansion, strategic partnerships and shareholder returns, while preserving a solid financial position.